Limber

LEADING IN MPNs BEYOND RUXOLITINIB.

Learn about ongoing clinical trials evaluating strategies to improve and expand treatments for patients with myeloproliferative neoplasms (MPNs), such as myelofibrosis (MF)

About Limber
About Limber
About Limber
About Limber
Incyte is a leader in the discovery and development of therapies for patients with MPNs. Despite the breakthrough advances brought by Incyte to patients with MPNs, a significant need for additional treatments still remains for those who have an inadequate response to or are unable to tolerate current therapies. The Leadership In MPNs BEyond Ruxolitinib (LIMBER) program is designed to evaluate multiple monotherapy and combination investigational strategies for patients with MPNs. The program currently has three key areas of focus: development of a new, once-daily formulation of ruxolitinib; ruxolitinib-based combinations with new targets such as PI3Kδ, BET and ALK2; and new therapeutic options. Two pivotal Phase 3 trials were recently initiated to evaluate the safety and efficacy of combination treatment with parsaclisib plus ruxolitinib in MF patients as first-line therapy (LIMBER-313) and in those who have had an inadequate or suboptimal response to ruxolitinib monotherapy (LIMBER-304). In addition, several other Phase 2 trials are ongoing to evaluate efficacy and safety of INCB57643 (BET) in patients with refractory MF; INCB00928 (ALK2) as monotherapy or in combination with ruxolitinib for patients with anemia due to MF; and itacitinib in patients with MF who have received prior ruxolitinib and/or fedratinib monotherapy.
Limber Trials
Limber Trials
Limber Trials
Limber Trials

What is limber 304?

This is a Phase 3 clinical study investigating the safety and efficacy of a potential treatment for patients with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.

Who is this study for?

This study is for patients over 18 years old with myelofibrosis who are already being treated with ruxolitinib, and have a potential need for further treatment in their doctor’s opinion.

Other limber trials
Other limber trials
Other limber trials
Other limber trials

Myelofibrosis

RRecruiting
Find out more
Myelofibrosis (MF)
Myelofibrosis (MF)
Myelofibrosis (MF)
Myelofibrosis (MF)

MF is a rare, chronic blood cancer. It can "progress," or get worse, over time. For example, new symptoms may appear or existing symptoms may get worse.1 MF is part of a group of diseases called "myeloproliferative neoplasms," or MPNs. Healthcare professionals sometimes call this condition a bone marrow cancer or blood cancer. Bone marrow is a spongy tissue inside of the bone, and is the primary place where blood cells are made. People with MF have a defect in their bone marrow that results in an abnormal production of blood cells, causing scar tissue to form. 2 MF can result from a progression of other bone marrow diseases or it can occur on its own.3

  • 1. LLS MF Facts, Mayo Clinic MF
  • 2. LLS MF Facts, Mayo Clinic MF, MPN Foundation
  • 3. LLS Fact Sheet
  • 4. Benter, 2011
  • 5. Chapman, 2020
  • 6. Mayo Clinic, Enlarged Spleen, 2012
  • 7. LLS MF Facts
  • 8. Verstovsek, CanRes, 2010
  • 9. Emmanuel, JCO, 2012
  • 10. Dorland
  • 11. Boissinot 2010

Copyright 2021 Incyte

Powered by: